{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1"}]}],"title":"Retreatment 1: Good Response (n = 304)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8"}]}],"title":"Retreatment 1: Moderate Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1"}]}],"title":"Retreatment 1: No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5"}]}],"title":"Retreatment 2: Good Response (n = 258)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3"}]}],"title":"Retreatment 2: Moderate Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1"}]}],"title":"Retreatment 2: No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6"}]}],"title":"Retreatment 3: Good Response (n = 227)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3"}]}],"title":"Retreatment 3: Moderate Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1"}]}],"title":"Retreatment 3: No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9"}]}],"title":"Retreatment 4: Good Response (n = 168)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.9"}]}],"title":"Retreatment 4: Moderate Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"}]}],"title":"Retreatment 4: No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4"}]}],"title":"Retreatment 5: Good Response (n = 132)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5"}]}],"title":"Retreatment 5: Moderate Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1"}]}],"title":"Retreatment 5: No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"}]}],"title":"Retreatment 6: Good Response (n = 87)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8"}]}],"title":"Retreatment 6: Moderate Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9"}]}],"title":"Retreatment 6: No Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"}],"units":"Participants"}],"description":"Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \\< -1.2 was a good response, \\< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \\> 3.2 to ≤ 5.1, a change from baseline of \\< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \\> 5.1, a change from baseline \\< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \\> 3.2. The first retreatment may have occurred in the precursor study WA17042.","groups":[{"description":"Participants received rituximab 1 g intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid ≥ 5 mg/week or equivalent, given as either a single dose or as divided daily doses.","id":"OG000","title":"Rituximab"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population: All participants who received any part of an infusion of study medication in study WA17531.","reportingStatus":"POSTED","timeFrame":"Baseline to the end of the retreatment period (up to 7 years, 6 months)","title":"Percentage of Participants With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}